• Home
  • Investor Relations
  • Corporate Governance
  • SEC Filings
  • Newsroom
Celularity
  • Home
  • Investor Relations
  • Corporate Governance
  • SEC Filings
  • Newsroom
  • Home
  • Investor Relations
  • Corporate Governance
  • SEC Filings
  • Newsroom
All rights reserved
Celularity
MENU

Celularity Inc.

Stock
Information

SEC Filings
Email Alerts
RSS Feed - SEC Filings
RSS Feed - Press Releases
Print Page
Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2025. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions

in
F.A.Q
Support Forum
Video Tutorials

Search panel can contain any widgets and shortcodes.

Call us: (908) 768 – 2170